JP2023524068A5 - - Google Patents
Info
- Publication number
- JP2023524068A5 JP2023524068A5 JP2022566336A JP2022566336A JP2023524068A5 JP 2023524068 A5 JP2023524068 A5 JP 2023524068A5 JP 2022566336 A JP2022566336 A JP 2022566336A JP 2022566336 A JP2022566336 A JP 2022566336A JP 2023524068 A5 JP2023524068 A5 JP 2023524068A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bcma
- region
- therapeutic agent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20172322.8 | 2020-04-30 | ||
| EP20172322 | 2020-04-30 | ||
| PCT/US2021/029877 WO2021222552A1 (en) | 2020-04-30 | 2021-04-29 | Methods of treating cytokine-related adverse events |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524068A JP2023524068A (ja) | 2023-06-08 |
| JP2023524068A5 true JP2023524068A5 (cg-RX-API-DMAC10.html) | 2024-05-09 |
Family
ID=70482328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566336A Withdrawn JP2023524068A (ja) | 2020-04-30 | 2021-04-29 | サイトカイン関連有害事象を治療する方法 |
Country Status (11)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| CA2992797A1 (en) | 2015-08-03 | 2017-02-09 | Engmab Sarl | Monoclonal antibodies against bcma |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| CN104797256A (zh) * | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
| CA2992797A1 (en) | 2015-08-03 | 2017-02-09 | Engmab Sarl | Monoclonal antibodies against bcma |
| US11959925B2 (en) * | 2017-04-17 | 2024-04-16 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug for use in humans |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| BR112020017053A2 (pt) * | 2018-02-21 | 2020-12-15 | Celgene Corporation | Anticorpos que se ligam ao bcma e usos dos mesmos |
| PL3796912T3 (pl) | 2018-05-23 | 2023-09-11 | Celgene Corporation | Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego |
-
2021
- 2021-04-29 AU AU2021263408A patent/AU2021263408A1/en not_active Abandoned
- 2021-04-29 CA CA3180173A patent/CA3180173A1/en active Pending
- 2021-04-29 IL IL297716A patent/IL297716A/en unknown
- 2021-04-29 MX MX2022013465A patent/MX2022013465A/es unknown
- 2021-04-29 US US17/921,893 patent/US20230172923A1/en not_active Abandoned
- 2021-04-29 CN CN202180043896.XA patent/CN115803027A/zh active Pending
- 2021-04-29 EP EP21726019.9A patent/EP4142722A1/en not_active Withdrawn
- 2021-04-29 KR KR1020227039875A patent/KR20230007384A/ko not_active Withdrawn
- 2021-04-29 JP JP2022566336A patent/JP2023524068A/ja not_active Withdrawn
- 2021-04-29 BR BR112022020673A patent/BR112022020673A2/pt not_active IP Right Cessation
- 2021-04-29 WO PCT/US2021/029877 patent/WO2021222552A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7493569B2 (ja) | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 | |
| van de Donk et al. | Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies | |
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| JP6877147B2 (ja) | 放射線療法と併用されるｐｄ−１およびｐｄ−ｌ１に対する拮抗薬を用いたがんの治療法 | |
| JP2020500181A5 (cg-RX-API-DMAC10.html) | ||
| US20160361360A1 (en) | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs | |
| US20240066040A1 (en) | Ep4 inhibitors and use thereof | |
| JP2009518441A5 (cg-RX-API-DMAC10.html) | ||
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| JP2023522857A5 (cg-RX-API-DMAC10.html) | ||
| JP2020503273A5 (cg-RX-API-DMAC10.html) | ||
| JP2014533279A5 (cg-RX-API-DMAC10.html) | ||
| RU2017112379A (ru) | Сочетанные способы лечения с использованием ингибиторов alk | |
| CN120939219A (zh) | 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合 | |
| EP3743061A1 (en) | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells | |
| JP2021530487A (ja) | Ｅｐ４阻害剤およびその合成 | |
| EP3066128A1 (en) | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma | |
| JP2024540275A5 (cg-RX-API-DMAC10.html) | ||
| JP2022508513A (ja) | がん治療のための併用療法 | |
| JP2023524430A5 (cg-RX-API-DMAC10.html) | ||
| CA3153777A1 (en) | Quantitative spatial profiling for lag-3 antagonist therapy | |
| JP2023513434A5 (cg-RX-API-DMAC10.html) | ||
| JP2024513054A5 (cg-RX-API-DMAC10.html) | ||
| US20220025061A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| JP2022554353A5 (cg-RX-API-DMAC10.html) |